Literature DB >> 12592349

Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome.

M W Drummond, C J Lush, M A Vickers, F M Reid, J Kaeda, T L Holyoake.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12592349     DOI： 10.1038/sj.leu.2402814

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  Uncovering Clinical Features of De Novo Philadelphia Positive Myelodysplasia.

Authors:  Aristides Armas; Chen Chen; Martha Mims; Gustavo Rivero
Journal:  Case Rep Hematol       Date:  2017-02-21

Review 2.  Concise Review: Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit.

Authors:  Haojian Zhang; Shaoguang Li
Journal:  Stem Cells Transl Med       Date:  2019-04-23       Impact factor: 6.940

Review 3.  HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?

Authors:  Hélène Losson; Michael Schnekenburger; Mario Dicato; Marc Diederich
Journal:  Cancers (Basel)       Date:  2020-01-29       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.